Molecular tumor markers in the blood: Early prediction of disease outcome in melanoma patients treated with a melanoma vaccine

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2558-2563

  Wascher, Robert A ^a   Morton, Donald L ^a   Kuo, Christine ^a   Elashoff, Robert M ^a   Wang, He Jing ^a   Gerami, Mehri ^a   Hoon, Dave S B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELAN A; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; TUMOR MARKER; CANCER VACCINE; MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; FOLLOW UP; HUMAN; HUMAN CELL; MELANOMA; ONCOGENE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT FAILURE; UNIVERSAL MELANOMA ANTIGEN GENE A; ADULT; AGED; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PREDICTION AND FORECASTING; RISK FACTOR; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0038013979     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.110     Document Type: Article

References (25)

1. Morton DL, Wanek L, Nizze JA, et al: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 214:491-495, 1991
2. Buzaid AC, Tinoco LA, Jendiroba D, et al: Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 13:2361-2368, 1995
3. Li W, Stall A, Shivers SC, et al: Clinical relevance of molecular staging for melanoma: Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 231:795-803, 2000
4. Bostick PJ, Morton DL, Turner RR, et al: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17:3238-3244, 1999
5. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1998). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Bethesda, MD, August 2000 submission, released April 2001
6. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
7. Morton DL, Hsueh EC, Essner R, et al: Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236:438-448, 2002
8. Chan AD, Morton DL: Active immunotherapy with allogeneic tumor cell vaccines: Present status. Semin Oncol 25:611-622, 1998
9. Morton DL, Foshag LJ, Hoon DS, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
10. Morton DL, Hoon DS, Nizze JA, et al: Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 690:120-134, 1993
11. Hoon DS, Foshag LJ, Nizze AS, et al: Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 50:5358-5364, 1990
12. Miyashiro I, Kuo C, Huynh K, et al: Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 47:505-512, 2001
13. Sarantou T, Chi DD, Garrison DA, et al: Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371-1376, 1997
14. Bostick PJ, Chatterjee S, Chi DD, et al: Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16:2632-2640, 1998
15. Bilchik AJ, Saha S, Wiese D, et al: Molecular staging of early colon cancer on the basis of sentinel node analysis: A multicenter phase II trial. J Clin Oncol 19:1128-1136, 2001
16. Hoon DS, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13:2109-2116, 1995
17. Klein JP, Moeschberger ML: Survival Analysis, Techniques for Censored and Truncated Data. New York, NY, Springer, 1997, pp 187-228
18. Klein JP, Moeschberger ML: Survival Analysis, Techniques for Censored and Truncated Data. New York, NY, Springer, 1997, pp 229-268
19. Fleming TR, Lin DY: Survival analysis in clinical trials: Past developments and future directions. Biometrics 56:971-983, 2000
20. Hoon DS, Bostick P, Kuo C, et al: Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60:2253-2257, 2000
21. Reinhold U, Berkin C, Bosserhoff AK, et al: Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: A multicenter study of the Dermatologic Cooperative Oncology Group. J Clin Oncol 19:1723-1727, 2001
22. Proebstle TM, Jiang W, Hogel J, et al: Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 82:118-123, 2000
23. Palmieri G, Strazzullo M, Ascierto PA, et al: Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression: Melanoma Cooperative Group. J Clin Oncol 17:304-311, 1999
24. Mellado B, Gutierrez L, Castel T, et al: Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 5:1843-1848, 1999
25. Morton DL, Essner R, Kirkwood JM, et al: Malignant melanoma, in Kufe DW, Pollock WE, Weichselbaum RR, et al (eds): Cancer Medicine (ed 5). Ontario, Canada, BC Decker, 2000, pp 1849-1869